Successfully, moclobemide; a reversible MAO-A inhibitor, has been approved for treatment of neuropsychiatric disorders, such as depression, whereas safinamide, a reversible MAO-B inhibitor, has been approved for neurodegenerative disorders, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Here, MAOB is linked to Parkinson disease.